ABSTRACT
It is well known the potential of severe acute respiratory coronavirus type 2 (SARS-CoV-2) infection to induce post-acute sequelae, a condition called Long COVID. This syndrome includes several symptoms, but the central nervous system (CNS) main one is neurocognitive dysfunction. Recently it has been demonstrated the relevance of plasma levels of neurofilament light chain (pNfL), as a biomarker of early involvement of the CNS in COVID-19. The aim of this study was to investigate the relationship between pNfL in patients with post-acute neurocognitive symptoms and the potential of NfL as a prognostic biomarker in these cases. A group of 63 long COVID patients ranging from 18 to 59 years-old were evaluated, submitted to a neurocognitive battery assessment, and subdivided in different groups, according to results. Plasma samples were collected during the long COVID assessment and used for measurement of pNfL with the Single molecule array (SIMOA) assays. Levels of pNfL were significantly higher in long COVID patients with neurocognitive symptoms when compared to HC (p = 0.0031). Long COVID patients with cognitive impairment and fatigue symptoms presented higher pNfL levels when compared to long COVID patients without these symptoms, individually and combined (p = 0.0263, p = 0.0480, and 0.0142, respectively). Correlation analysis showed that levels of cognitive lost and exacerbation of fatigue in the neurocognitive evaluation had a significative correlation with higher pNfL levels (p = 0.0219 and 0.0255, respectively). Previous reports suggested that pNfL levels are related with higher risk of severity and predict lethality of COVID-19. Our findings demonstrate that SARS-CoV-2 infection seems to have a long-term impact on the brain, even in patients who presented mild acute disease. NfL measurements might be useful to identify CNS involvement in long COVID associated with neurocognitive symptoms and to identify who will need continuous monitoring and treatment support.
ABSTRACT
INTRODUCTION: Coronavirus disease 19 (COVID-19) affected the health-related quality of life (HRQoL), and its impact on well-being is not sufficiently understood yet. The worsening of HRQoL and symptoms such as fatigue, anxiety, depression, chronic Headache, Myalgia, ageusia, olfactory disorders, and cognitive impairment can be seen in people of different ages and genders after COVID-19 infection, even mild infections without hospitalization. These issues generate a disease burden that can reduce work skills and cause social, psychological, and neuropsychiatric challenges. OBJECTIVE: To evaluate the HRQoL of patients affected by COVID-19, the domains most affected, and their relationship with fatigue, anxiety, depression, chronic Headache and Myalgia, ageusia, olfactory disorders, and cognitive impairment. METHODS: An analytical transverse was conducted with 143 patients after COVID-19 infection. The patient-reported outcomes measures (PROMS) were collected by the 36-item Short Form survey (SF-36), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), Mini-Mental State Examination-2 (MMSE-2), Symbol Digit Modalities Test (SDMT), and a questionnaire regarding symptoms such as chronic Headache, myalgia, and olfactory disorders. Spearman's correlation test was used to correlate the performance of the patients on different PROMS. RESULTS: Fatigue, depression, and anxiety were negatively correlated with all the SF-36 domains, and patients with subjective cognitive complaints had low scores in all SF-36 domains. Furthermore, those with chronic Headaches had low scores in physical functioning, role-physical functioning, and vitality. Regarding myalgia complaints, the worst scores were observed in the physical functioning and vitality domains. Patients with ageusia had low scores in general health perceptions, and those with olfactory dysfunction had low scores in the vitality and mental health domains. CONCLUSIONS: Although the acute phase of COVID-19 has resolved, knowledge about HRQoL after this period is essential since many individual and collective changes have been taking place until today-patients with neuropsychiatric manifestations that persisted after the acute phase showed lower overall quality of life.
Subject(s)
COVID-19 , Depression , Fatigue , Quality of Life , Humans , COVID-19/psychology , Quality of Life/psychology , Male , Female , Middle Aged , Adult , Anxiety/psychology , Cognitive Dysfunction/physiopathology , Aged , Myalgia , Patient Reported Outcome Measures , Ageusia , Olfaction Disorders , SARS-CoV-2 , HeadacheABSTRACT
BACKGROUND: Autoimmune encephalitis (AIE) is a group of inflammatory diseases characterized by the presence of antibodies against neuronal and glial antigens, leading to subacute psychiatric symptoms, memory complaints, and movement disorders. The patients are predominantly young, and delays in treatment are associated with worse prognosis. OBJECTIVE: With the support of the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN) and the Brazilian Society of Child Neurology (Sociedade Brasileira de Neurologia Infantil, SBNI), a consensus on the diagnosis and treatment of AIE in Brazil was developed using the Delphi method. METHODS: A total of 25 panelists, including adult and child neurologists, participated in the study. RESULTS: The panelists agreed that patients fulfilling criteria for possible AIE should be screened for antineuronal antibodies in the serum and cerebrospinal fluid (CSF) using the tissue-based assay (TBA) and cell-based assay (CBA) techniques. Children should also be screened for anti-myelin oligodendrocyte glucoprotein antibodies (anti-MOG). Treatment should be started within the first 4 weeks of symptoms. The first-line option is methylprednisolone plus intravenous immunoglobulin (IVIG) or plasmapheresis, the second-line includes rituximab and/or cyclophosphamide, while third-line treatment options are bortezomib and tocilizumab. Most seizures in AIE are symptomatic, and antiseizure medications may be weaned after the acute stage. In anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, the panelists have agreed that oral immunosuppressant agents should not be used. Patients should be evaluated at the acute and postacute stages using functional and cognitive scales, such as the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Modified Rankin Scale (mRS), and the Clinical Assessment Scale in Autoimmune Encephalitis (CASE). CONCLUSION: The present study provides tangible evidence for the effective management of AIE patients within the Brazilian healthcare system.
ANTECEDENTES: Encefalites autoimunes (EAIs) são um grupo de doenças inflamatórias caracterizadas pela presença de anticorpos contra antígenos neuronais e gliais, que ocasionam sintomas psiquiátricos subagudos, queixas de memória e distúrbios anormais do movimento. A maioria dos pacientes é jovem, e o atraso no tratamento está associado a pior prognóstico. OBJETIVO: Com o apoio da Academia Brasileira de Neurologia (ABN) e da Sociedade Brasileira de Neurologia Infantil (SBNI), desenvolvemos um consenso sobre o diagnóstico e o tratamento da EAIs no Brasil utilizando a metodologia Delphi. MéTODOS: Um total de 25 especialistas, incluindo neurologistas e neurologistas infantis, foram convidados a participar. RESULTADOS: Os especialistas concordaram que os pacientes com critérios de possíveis EAIs devem ser submetidos ao rastreio de anticorpos antineuronais no soro e no líquido cefalorraquidiano (LCR) por meio das técnicas de ensaio baseado em tecidos (tissue-based assay, TBA, em inglês) e ensaio baseado em células (cell-based assay, CBA, em inglês). As crianças também devem ser submetidas ao rastreio de de anticorpo contra a glicoproteína da mielina de oligodendrócitos (anti-myelin oligodendrocyte glycoprotein, anti-MOG, em inglês). O tratamento deve ser iniciado dentro das primeiras 4 semanas dos sintomas, sendo as opções de primeira linha metilprednisolona combinada com imunoglobulina intravenosa (IGIV) ou plasmaférese. O tratamento de segunda linha inclui rituximabe e ciclofosfamida. Bortezomib e tocilizumab são opções de tratamento de terceira linha. A maioria das crises epilépticas nas EAIs são sintomáticas, e os fármacos anticrise podem ser desmamadas após a fase aguda. Em relação à encefalite antirreceptor de N-metil-D-aspartato (anti-N-methyl-D-aspartate receptor, anti-NMDAR, em inglês), os especialistas concordaram que agentes imunossupressores orais não devem ser usados. Os pacientes devem ser avaliados na fase aguda e pós-aguda mediante escalas funcionais e cognitivas, como Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Modified Rankin Scale (mRS), e Clinical Assessment Scale in Autoimmune Encephalitis (CASE). CONCLUSãO: Esta pesquisa oferece evidências tangíveis do manejo efetivo de pacientes com EAIs no sistema de saúde Brasileiro.
Subject(s)
Consensus , Encephalitis , Humans , Encephalitis/diagnosis , Encephalitis/therapy , Encephalitis/immunology , Brazil , Child , Adult , Hashimoto Disease/diagnosis , Hashimoto Disease/therapy , Delphi Technique , Autoantibodies/bloodABSTRACT
ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.
RESUMO O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que é melhor para cada paciente, com base em evidências e práticas atualizadas. Por meio deste documento, propomos recomendações práticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratégias de tratamento na EM.
Subject(s)
Humans , Vitamin D/therapeutic use , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Multiple Sclerosis/drug therapy , Recurrence , Brazil , Academies and Institutes , NeurologyABSTRACT
ABSTRACT The existence of a benign multiple sclerosis (BMS) form is a controversial subject. Recent studies of these patients reveal different levels of cognitive impairment, despite the apparent preservation of motor function. The objective of this study was to review and analyze a number of publications that discuss the general aspects of this disease form, such as the definition criteria, prevalence, and clinical and neuroimaging markers. A systematic review of published data on BMS up to October 2015 was performed. Thirty-one published articles were analyzed. The estimated frequency of BMS varied between 6% and 73%. Cognitive impairment was recognized as affecting 17% to 47% of the subjects and presented significant correlation with neuroimaging, such as brain atrophy, increased lesion volume in T2 magnetic resonance assay, and regional grey matter atrophy. The current criteria overestimated the frequency of BMS and, for that reason, this highlights the importance of validating the diagnostic methods practiced.
RESUMO A existência real de uma forma benigna da esclerose múltipla (EMB) é um tema controverso. Ampliar o número de publicações que abordam os aspectos gerais do subtipo da doença, tais como os critérios de definição utilizados, análise de prevalência e da presença de marcadores clínicos e de neuroimagem. Foi realizada uma revisão sistemática dos dados publicados até outubro de 2015, relativa à EMB. Os dados encontrados foram dicotomizados em gráficos e, posteriormente, analisados. Foram analisados 31 artigos publicados. A frequência estimada EMB oscila entre 6% a 73%. O comprometimento cognitivo foi reconhecido em 17–47% dos sujeitos, apresentando correlação significativa com os aspectos de neuroimagem, como a atrofia cerebral global, aumento do volume lesional em T2 e atrofia regional da substância cinzenta. Os critérios atualmente utilizados superestimam a freqüência de EMB, e, por essa razão, destaca-se a importância da validação dos métodos de diagnóstico praticados.
Subject(s)
Humans , Cognition Disorders/etiology , Cognition Disorders/pathology , Cognition Disorders/diagnostic imaging , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Multiple Sclerosis/diagnostic imaging , NeuroimagingABSTRACT
ABSTRACT Patients with malignant multiple sclerosis (MMS) reach a significant level of disability within a short period of time (Expanded Disability Status Scale score of 6 within five years). The clinical profile and progression of the disease were analyzed in a Brazilian cohort of 293 patients. Twenty-five (8,53%) patients were found to have MMS and were compared with the remaining 268 (91,47%). Women, non-white patients, older age at disease onset, shorter intervals between the first attacks, and more attacks in the first two years of the disease were all more common in the MMS group. These findings could serve as prognostic factors when making therapeutic decisions.
RESUMO Os doentes com esclerose múltipla maligna (EMM) atingem um nível significativo de incapacidade dentro de um curto período de tempo (EDSS 6 em até 5 anos desde primeiro sintoma/sinal da doença). O perfil clínico e progressão da doença foram analisados em uma coorte brasileira de 293 pacientes. Vinte e cinco (8,53%) pacientes foram encontrados com EMM e foram comparados com os restantes 268 (91,47%). Mulheres, pacientes não-brancos, idade mais avançada no início da doença, intervalos mais curtos entre os primeiros ataques e, mais ataques nos dois primeiros anos da doença, foram mais comuns no grupo com EMM. Estes achados podem servir como fatores prognósticos na tomada de decisão terapêutica.
Subject(s)
Humans , Female , Adult , Middle Aged , Multiple Sclerosis/physiopathology , Prognosis , Severity of Illness Index , Retrospective Studies , Disease Progression , Disability Evaluation , Multiple Sclerosis/complicationsABSTRACT
ABSTRACT Multiple sclerosis (MS) prevalence is higher in Caucasian (CA) populations, narrowing the analysis of the impact of Afro-descendant (AD) populations in disease outcomes. Even so, recent studies observed that AD patients have a more severe course. The main objective of this study is to confirm and discuss, through a systematic review, that being AD is a risk factor for disability accumulation and/or severe progression in patients with MS. A systematic review of published data in the last eleven years was performed, which evaluated clinical aspects and long term disability in patients with MS. Fourteen studies were included. Of these fourteen articles, thirteen observed a relationship between ancestry and poorer outcome of MS. African ancestry is a condition inherent in the patient and should be considered as an initial clinical characteristic affecting prognosis, and influencing which therapeutic decision to make in initial phases.
RESUMO A prevalência da esclerose múltipla (EM) é maior em populações caucasianas (CA), o que limita a análise do impacto da Afrodescendencia (AD) nos desfechos da doença. Apesar disto, estudos recentes observaram que a AD determina um curso clínico mais severo. O principal objetivo deste estudo é confirmar e discutir, por meio de uma revisão sistemática, que a afrodescendência é um fator de risco para acúmulo de incapacidade e/ou progressão mais severa em pacientes com EM. Foi realizada uma revisão sistemática de trabalhos publicados nos últimos onze anos que avaliaram aspectos clínicos e incapacidade a longo prazo em pacientes com EM. Quatorze artigos foram incluídos. Entre eles, treze observaram uma relação entre AD e pior prognóstico da EM. AD é uma condição inerente ao paciente e deveria ser considerada, assim como as características clínicas relacionadas ao prognóstico, influenciando a decisão terapêutica a ser tomada nas fases iniciais da doença.
Subject(s)
Humans , Male , Female , Disease Progression , Black People , Disability Evaluation , Multiple Sclerosis/ethnology , Multiple Sclerosis/physiopathology , Prognosis , Severity of Illness Index , Risk Factors , Multiple Sclerosis/pathologyABSTRACT
Objective: To investigate cognitive deficits in patients with primary Sjögren’s syndrome (PSS). Method: Eighteen patients with PSS, aged between 25 and 61 years, were subjected to a short neuropsychological battery and compared with 18 patients with multiple sclerosis and 18 healthy controls. Results: The analysis of variance (ANOVA) revealed that the clinical groups had significantly worse performance than the control group on the Rey Auditory Verbal Learning Test 3; (F 2,53 =3.500, p=0.038) and 7 (F 2,53 =5.068, p=0.010). The clinical groups had elevated levels of depression on the Beck Depression Inventory (BDI); (p=0.003). The analysis of the data from the Trail Making Test B-A revealed a significant difference between the clinical and control groups (p=0.023). The analysis of covariance with BDI score as a covariate, did not change the outcome. Conclusion: Our study revealed cognitive deficits in patients with PSS detectable by a short neuropsychological battery. .
Objetivo: Investigar déficits cognitivos em pacientes com síndrome de Sjögren primária (SSP) utilizando bateria neuropsicológica breve. Método: Dezoito pacientes com SSP e idade entre 25 e 61 anos, foram submetidos a uma bateria neuropsicológica breve e os resultados comparados com 18 pacientes com esclerose múltipla e com 18 controles saudáveis. Resultados: A análise da variância revelou que os grupos clínicos apresentaram desempenho significativamente pior que os controles ao Rey Auditory Verbal Learning Test 3 (RAVLT 3; F 2,53 =3,500, p=0,038) e RAVLT 7 (F 2,53 =5,068, p=0,010). Os grupos clínicos apresentaram índices elevados de depressão pela Beck Depression Inventor y (BDI); (F 2,53 =0.003). O desempenho no Trail Making Test B-A revelou diferença significativa entre os grupos clínicos e o grupo controle (p=0,023). A análise de covariância tomando a BDI como covariante, não revelou mudanças nos resultados. Conclusão: Nosso estudo revelou comprometimento cognitivo em pacientes com SSP detectável por bateria neuropsicológica breve. .
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Cognition Disorders/psychology , Neuropsychological Tests , Sjogren's Syndrome/psychology , Analysis of Variance , Case-Control Studies , Cognition Disorders/diagnosis , Cognition Disorders/physiopathology , Depression/diagnosis , Depression/physiopathology , Reference Values , Reproducibility of Results , Sjogren's Syndrome/physiopathologyABSTRACT
Após a dissecção de cérebro de uma paciente em 1868, Charcot definiu uma evidência histopatológica mais assertiva para a esclerose múltipla (EM): "sclerose en plaque". Entretanto, mais de um século depois, poucos estudos examinando o substrato patológico específico de fenótipos clínicos diferentes da EM são encontrados na literatura. O objetivo deste estudo é uma revisão da literatura sobre achados post-mortem (autopsia, exame histopatológico e técnicas imuno-histoquímicas) em pacientes com EM. Utilizando os termos "autopsy", "necropsy", "pathology", "post-mortem" e "multiple sclerosis", a pesquisa foi desenvolvida sobre a literatura e recursos presentes no MEDLINE no período janeiro 1990 a agosto 2012. Artigos relevantes baseados em análise macro/microscópica das lesões da EM e o uso de técnicas imuno-histoquímicas (marcadores imunológicos e neurobiológicos) foram revistos. Tratados de patologia cirúrgica e neuropatologia em suas últimas edições foram também consultados. Além dos estudos no início dos anos 2000 que identificaram padrões diferentes de desmielinização em casos de autópsia, considerando a perda de mielina, a geografia e extensão das lesões, a destruição dos oligodendrócitos e a evidência do dano imunopatológico, estudos mais detalhados e baseados em aspectos anatomopatológicos e implicações patogênicas são raros. A maioria destes poucos e específicos estudos reportam que as lesões da EM tipicamente aparecem na substância branca, mas são também abundantes na substância cinza, heterogeneidade de lesões inter-paciente e homogeneidade intra-paciente, graus diferentes para perda de mielina e estágios de atividade, foco de atividade inflamatória que origina gliose fibrilar, distrofia de oligodendrócitos e densidade axonal central diminuída. Desmielinização é um importante indicador de progressão clínica e a remielinização pode ser incompleta ou decresce com a cronicidade da doença. A importância das lesões na substância branca de aparência normal e na substância cinzenta tem sido cada vez mais reconhecida em recentes estudos com técnicas imuno-histoquímicas. Não há ainda um consenso se as diferenças entre as formas clínicas são fundamentalmente quantitativas ou qualitativas em relação ao substrato patológico e mais estudos sobre autopsias utilizando exame histopatológico e técnicas modernas de imuno-histoquímica são necessários para dirimir esta questão. Um melhor entendimento sobre a heterogeneidade das lesões da esclerose múltipla proporcionará o desenvolvimento de métodos terapêuticos mais direcionados e eficazes.
After dissection of a female brain in 1868, Charcot outlined a more assertive histopathological evidence of Multiple Sclerosis: "sclerose en plaque". However, more than a century later, very few studies examining the specific underlying pathology of a defined MS clinical phenotype are found in literature. The purpose of this study is to provide a literature review of post-mortem findings (histopathology and immunohistochemical techniques) in MS patients. The literature in MEDLINE was searched from January 1990 to August 2012 using the terms "autopsy", "necropsy", "pathology", "postmortem" and "multiple sclerosis". Relevant papers based on macroscopic/microscopic analysis of the MS lesions and the use of broad spectrum of immunological and neurobiological markers (immunohistochemistry) were reviewed. Textbooks of Surgical Pathology and Neuropathology in latest editions were also consulted.Besides the studies in the early 2000s that identified different patterns of demyelination in autopsy cases, consider the myelin impairment, the geography and extension of lesions, the oligodendrocyte destruction and the evidence of immunopathological damage, more detailed studies based on anatomopathological aspects and pathogenic implications are rare. Most of these few specific studies reported that MS lesions typically appear in the white matter, but are also abundant in grey matter, inter-patient lesions heterogeneity with intra-patient homogeneity, different degree of myelin loss and stage of activity, focus of inflammatory activity that gives way to fibrillary gliosis, oligodendrocyte dystrophy and decreased central axonal density. Demyelination is an important pathological correlate of clinical progression and remyelination could be incomplete or decreases with disease chronicity. The importance of healthy-appearing white matter damage and grey matter demyelination has been increasingly recognized in recent studies using immunohistochemical techniques. There is still no consensus on whether the differences between the clinical forms of MS are fundamentally quantitative or qualitative in relation to the pathological substrate, and more detailed studies with data on autopsies is required to resolve this issue. A better understanding of the pathogenetic heterogeneity of MS lesions will lead the development of more effective treatment methods.
Subject(s)
Humans , Male , Female , Adult , Inflammation/immunology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Immunohistochemistry/methods , Biomarkers , Demyelinating Autoimmune Diseases, CNSABSTRACT
Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests. OBJECTIVE: To investigate cognitive profiles of Brazilian patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) by using a brief battery of neuropsychological tests. METHOD: Sixty-six patients, within 18-65 of age and 3-18 years of education, were paired with healthy control subjects, regarding gender, age, and education level. RESULTS: On Symbol Digit Modalities Test and Hooper Visual Organization Test, cognition was affected in 50 percent in RRMS and 69 percent in PPMS. Fluency of "F" was impaired in 24 percent of RRMS and 81 percent of PPMS. Immediate recall was affected in 32 percent of RRMS and in 63 percent of PPMS; whereas late recall, in 46 percent of relapsing-remitting and in 69 percent of primary progressive. CONCLUSION: Cognitive profiles of relapsing-remitting and primary progressive patients are different.
O comprometimento cognitivo é um sintoma da esclerose múltipla (EM). Formas clínicas diferentes da EM apresentam diferentes perfis cognitivos, de acordo com resultados de estudos anteriores que usaram bateria extensa de testes neuropsicológicos. OBJETIVO: Investigar o perfil cognitivo de pacientes com esclerose múltipla remitente-recorrente (EMRR) e esclerose múltipla progressiva primária (EMPP) utilizando uma bateria neuropsicológica breve. MÉTODO: 66 pacientes com idade de 18 a 65 anos, escolaridade 3 a 18 anos, foram pareados a controles por sexo, idade e escolaridade; e avaliados. RESULTADO: No Symbol Digit Modalitie Test e Hooper Visual Organization Test 50 por cento com EMRR e 69 por cento com EMPP apresentaram desempenho comprometido. Na fluência da letra "F" o comprometimento foi de 24 por cento daqueles com EMRR e 81 por cento com EMPP. Na evocação imediata o comprometimento foi de 32 por cento na EMRR e 63 por cento na EMPP e, evocação tardia em 46 por cento na remitente-recorrente e 69 por cento com progressiva primária. CONCLUSÃO: Os perfis cognitivos dos pacientes com esclerose múltipla remitente-recorrente e progressiva primária são diferentes.